SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001387131-21-012403
Filing Date
2021-12-30
Accepted
2021-12-30 16:33:02
Documents
3
Group Members
ALBERT CHAFHMLS X, L.L.C.FHMLS X, L.P.FHMLSP, L.L.C.FHMLSP, L.P.FRAZIER LIFE SCIENCES X, L.P.JAMES BRUSHJAMES N. TOPPERPATRICK J. HERON

Document Format Files

Seq Description Document Type Size
1 ACQUISITION OF BENEFICIAL OWNERSHIP kalv-sc13d_122121.htm SC 13D 351539
3 JOINT FILING AGREEMENT ex99-1.htm EX-99.1 16791
4 GRAPHIC kalv-01.jpg GRAPHIC 15691
  Complete submission text file 0001387131-21-012403.txt   386830
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Subject) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: SC 13D | Act: 34 | File No.: 005-88797 | Film No.: 211533225
SIC: 2834 Pharmaceutical Preparations

Mailing Address TWO UNION SQUARE, 601 UNION ST. SUITE 3200 SEATTLE WA 98101
Business Address TWO UNION SQUARE, 601 UNION ST. SUITE 3200 SEATTLE WA 98101 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

IRS No.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D